Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine and Venetoclax in Patients with Acute Myeloid Leukemia (ASPEN-05): Results from Phase 1a Dose Escalation Part

Guillermo Garcia-Manero, Amanda Przespolewski, Yasmin Abaza, Michael Byrne, Abraham P. Fong, Feng Jin, Alison J. Forgie, Athanasios C. Tsiatis, Shanhong Guan, Harry P. Erba

Blood (2022) 140 (Supplement 1): 9046–9047.

https://doi.org/10.1182/blood-2022-157606

Published: 2022

Journal Articles

Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine: A Phase 1 / 2 Study in Patients with Myelodysplastic Syndrome (ASPEN-02)

Guillermo Garcia-Manero, Harry P. Erba, Srinivasa R. Sanikommu, Jessica K. Altman, Hamid Sayar, Bart L. Scott, Abraham P. Fong, Shanhong Guan, Feng Jin, Alison J. Forgie, Jaume Pons, Sophia S. Randolph, Michael T. Byrne

Blood (2021) 138 (Supplement 1): 2601.

https://doi.org/10.1182/blood-2021-146547

Published: 2021

Journal Articles

ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma

Tae Min Kim, MD PhD, Nehal Lakhani, MD PhD, Justin Gainor, MD, Manali Kamdar, MD, Philip Fanning, PhD, Pierre Squifflet, MSc, Feng Jin, PhD, Alison J. Forgie, PhD, Hong Wan, PhD, Jaume Pons, PhD, Sophia S Randolph, MDPhD, Won Seog Kim, MD PhD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-135941

Published: 2020

Journal Articles

A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma

Tae Min Kim, MD PhD, Nehal Lakhani, MD PhD, Justin Gainor, MD, Manali Kamdar, MD MD, Philip Fanning, PhD, Pierre Squifflet, MSc, Feng Jin, PhD, Hong Wan, PhD, Jaume Pons, PhD, Sophia S Randolph, MD PhD, Won Seog Kim, MD PhD

Blood (2019) 134 (Supplement_1): 1953.

https://doi.org/10.1182/blood-2019-123219

Published: 2019

Journal Articles

Population Pharmacokinetics of Bruton Tyrosine Kinase Inhibitor, Acalabrutinib, in Healthy Volunteers and Patients with B-Cell Malignancies

Helena Edlund, PhD, Marilee Andrew, PhD, Feng Jin, PhD, Priti Patel, MD, Eric Masson, PharmD, J. Greg Slatter, PhD, Sergey Aksenov, PhD, Nidal Al-Huniti, PhD

Blood (2017) 130 (Supplement 1): 4997.

https://doi.org/10.1182/blood.V130.Suppl_1.4997.4997

Published: 2017

Journal Articles

Exposure-Response of the Bruton Tyrosine Kinase Inhibitor, Acalabrutinib, in the Treatment of Hematologic Malignancies

Feng Jin, PhD, Ming Yin, PhD, Vinay Mandava, Helena Edlund, PhD, Marilee Andrew, PhD, Priti Patel, MD, Eric Masson, PharmD, Nidal Al-Huniti, PhD, Xiaolin Wang, ScD, J. Greg Slatter, PhD

Blood (2017) 130 (Supplement 1): 1268.

https://doi.org/10.1182/blood.V130.Suppl_1.1268.1268

Published: 2017

Journal Articles

Exposure-Response of Idelalisib Administered in Combination with Ofatumumab for the Treatment of Relapsed Chronic Lymphocytic Leukemia

Shringi Sharma, PhD, Ying Guo, PhD, Feng Jin, PhD, Xiaoming Li, PhD, Ronald L. Dubowy, MD, Terry Newcomb, PhD, Srini Ramanathan, PhD

Blood (2015) 126 (23): 4172.

https://doi.org/10.1182/blood.V126.23.4172.4172

Published: 2015

Journal Articles

Antithymocyte Globulin Treatment at the Time of Transplantation Impairs Donor Hematopoietic Stem Cell Engraftment

Zheng Hu, PhD, Feng Jin, Jin He, Chunhui Jin, Wei Fan, Yanhong Shan, Zefeng Zhang, Liguang Sun, Yong-Guang Yang, MD PhD

Blood (2015) 126 (23): 1872.

https://doi.org/10.1182/blood.V126.23.1872.1872

Published: 2015

Journal Articles

Phase 2 Trial Of GS-9973, a Selective Syk Inhibitor, In Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)

Jeff P. Sharman, MD, Leonard Klein, MD, Michael Boxer, MD, Kathryn S. Kolibaba, MD, Michael J. Hawkins, MD, Julie A Di Paolo, PhD, Jing Hu, Ph.D, Anita Reddy, PhD, Feng Jin, PhD, Flordeliza Melchor-Khan, BS, Christopher A. Yasenchak, MD

Blood (2013) 122 (21): 1634.

https://doi.org/10.1182/blood.V122.21.1634.1634

Published: 2013

Journal Articles

Pharmacokinetics, Metabolism and Excretion Of Idelalisib

Feng Jin, PhD, Michelle Robeson, ND, Huafeng Zhou, PhD, Ellen Kwan, Srini Ramanathan, PhD

Blood (2013) 122 (21): 5570.

https://doi.org/10.1182/blood.V122.21.5570.5570

Published: 2013

Journal Articles

The Pharmacokinetics and Safety Of Idelalisib In Subjects With Moderate Or Severe Hepatic Impairment

Feng Jin, PhD, Michelle Robeson, ND, Huafeng Zhou, PhD, Grace Hisoire, Srini Ramanathan, PhD

Blood (2013) 122 (21): 5571.

https://doi.org/10.1182/blood.V122.21.5571.5571

Published: 2013

Journal Articles

The Pharmacokinetics and Safety Of Idelalisib In Subjects With Severe Renal Impairment

Feng Jin, PhD, Michelle Robeson, ND, Huafeng Zhou, PhD, Grace Hisoire, Srini Ramanathan, PhD

Blood (2013) 122 (21): 5572.

https://doi.org/10.1182/blood.V122.21.5572.5572

Published: 2013

Journal Articles

Evaluation Of The Effect Of Idelalisib On The QT/QTc Interval In Healthy Subjects

Feng Jin, PhD, Michelle Robeson, ND, Huafeng Zhou, PhD, Andie Nichols, Srini Ramanathan, PhD

Blood (2013) 122 (21): 5573.

https://doi.org/10.1182/blood.V122.21.5573.5573

Published: 2013

Journal Articles

Evaluation Of Drug Interaction Profile Of Idelalisib and Its Major Circulating Metabolite, GS-563117, In Healthy Subjects

Feng Jin, PhD, Michelle Robeson, ND, Huafeng Zhou, PhD, Candra Moyer, Sibylle Wilbert, PhD, Bernard Murray, PhD, Srini Ramanathan, PhD

Blood (2013) 122 (21): 5574.

https://doi.org/10.1182/blood.V122.21.5574.5574

Published: 2013

Journal Articles

Pharmacokinetics and Safety Of Idelalisib, a Novel PI3Kδ Inhibitor, In Japanese and Caucasian Subjects

Feng Jin, PhD, Michelle Robeson, ND, Huafeng Zhou, PhD, Candra Moyer, Srini Ramanathan, PhD

Blood (2013) 122 (21): 5575.

https://doi.org/10.1182/blood.V122.21.5575.5575

Published: 2013

Journal Articles

Exposure-Response Of Idelalisib, a Novel PI3Kδ Inhibitor, Administered As Monotherapy In The Treatment Of Hematologic Malignancies

Feng Jin, PhD, Huafeng Zhou, PhD, Lorna Fang, Xiaoming Li, PhD, Terry Newcomb, MD, Roger Dansey, MD, Srini Ramanathan, PhD

Blood (2013) 122 (21): 5054.

https://doi.org/10.1182/blood.V122.21.5054.5054

Published: 2013

NARROW

Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine and Venetoclax in Patients with Acute Myeloid Leukemia (ASPEN-05): Results from Phase 1a Dose Escalation Part

Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine: A Phase 1 / 2 Study in Patients with Myelodysplastic Syndrome (ASPEN-02)

ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma

A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma

Population Pharmacokinetics of Bruton Tyrosine Kinase Inhibitor, Acalabrutinib, in Healthy Volunteers and Patients with B-Cell Malignancies

Exposure-Response of the Bruton Tyrosine Kinase Inhibitor, Acalabrutinib, in the Treatment of Hematologic Malignancies

Exposure-Response of Idelalisib Administered in Combination with Ofatumumab for the Treatment of Relapsed Chronic Lymphocytic Leukemia

Antithymocyte Globulin Treatment at the Time of Transplantation Impairs Donor Hematopoietic Stem Cell Engraftment

Phase 2 Trial Of GS-9973, a Selective Syk Inhibitor, In Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)

Pharmacokinetics, Metabolism and Excretion Of Idelalisib

The Pharmacokinetics and Safety Of Idelalisib In Subjects With Moderate Or Severe Hepatic Impairment

The Pharmacokinetics and Safety Of Idelalisib In Subjects With Severe Renal Impairment

Evaluation Of The Effect Of Idelalisib On The QT/QTc Interval In Healthy Subjects

Evaluation Of Drug Interaction Profile Of Idelalisib and Its Major Circulating Metabolite, GS-563117, In Healthy Subjects

Pharmacokinetics and Safety Of Idelalisib, a Novel PI3Kδ Inhibitor, In Japanese and Caucasian Subjects

Exposure-Response Of Idelalisib, a Novel PI3Kδ Inhibitor, Administered As Monotherapy In The Treatment Of Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only